Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) filed Chapter 11 on November 2, 2026 with a USD 110 million superpriority debtor-in-possession loan, and anticipates that its current Equity will be worth nothing.
  • Medical Properties Trust (NYSE:MPT) reported third quarter 2026 Net Income near USD 202 million, but normalized funds from operations declined to roughly USD 64 million from about USD 77 million.
  • Claros Mortgage Trust (NYSE:CMTG) recorded a third quarter GAAP net loss of USD 14.3 million, and published market data showed USD 1.87 following an unverified 68.71% advance.
  • SelectQuote (NYSE:SLQT) faces a stockholder vote on November 10, 2026 on a reverse split ranging from 1-for-10 to 1-for-20, prompted by an NYSE notice over an average price below USD 1.00.

Karyopharm Therapeutics (NASDAQ:KPTI): Chapter 11, a USD 110 Million Loan and Cancelled Equity

Karyopharm Therapeutics (NASDAQ:KPTI), a drugmaker in commercial operation headquartered in Newton, Massachusetts, reported in a Form 8-K dated November 2, 2026 that it had entered a restructuring support agreement and begun voluntary Chapter 11 cases in the Southern District of Texas. The proposal calls for private firm Ayrmid Ltd. to merge with a reorganized Karyopharm, with closing expected in the first quarter of 2027, while bidding rules would allow rivals to file competing proposals. Karyopharm wants a USD 110 million superpriority debtor-in-possession term loan, with up to USD 55 million in new funds and the balance rolling existing loans, maturing May 1, 2027 at the latest. Under the filing, common and convertible Preferred Shares would receive nothing. Warning signs predated the filing: the March 31, 2026 Quarterly Report showed cash of USD 90.9 million, term loan principal of USD 124.6 million, a stockholders' Deficit of USD 265.6 million and doubt about continuing as a going concern. Published market data put KPTI near USD 0.10, a 9.17% gain, on about 24.457 million shares, but the snapshot date could not be confirmed, so those figures remain unverified.

Medical Properties Trust (NYSE:MPT): Asset Sale Gains Mask a Softer Core Measure

Medical Properties Trust (NYSE:MPT) released third quarter 2026 results on October 29, 2026. Reported net income of roughly USD 202 million was pushed up by USD 158 million of aggregate gains on asset sales and a USD 70 million gain linked to refinancing, while total Revenue rose from USD 237.5 million to USD 250.1 million. The company owns hospital properties and rents them to operators, so divestitures reshape both reported Earnings and future rent collections. Normalized funds from operations (FFO), a yardstick many property investors favor, dropped to about USD 64 million, or USD 0.11 per share. Net Debt stood at USD 9.26 billion at September 30, 2026, against USD 599 million of cash. Management attributed about USD 0.02 of normalized FFO shortfall in the quarter to HSA missing its September rent because of revenue cycle troubles. The stock quoted at USD 2.12, up 4.95% on 4.697 million shares in an undated snapshot, and a Penny Stock of this kind can be moved by a few trades. Filings employ the MPT symbol while the screen displayed MPW, apparently an older ticker, and the tag was not independently confirmed.

Claros Mortgage Trust (NYSE:CMTG): A Third Quarter Loss and a Price Far Below Book Value

Claros Mortgage Trust (NYSE:CMTG) disclosed third quarter 2026 results on November 3, 2026. As a Commercial Real Estate lender, it posted a distributable loss of USD 12.1 million, or USD 0.08 per share, along with a GAAP net loss of USD 14.3 million, or USD 0.10 per share. Book Value came to USD 8.49 per share, with net debt to equity at 1.7x, or 1.5x after USD 268.7 million of loan repayments on a pro forma basis. Expected Credit loss reserves totaled USD 566.2 million, equal to 18.5% of unpaid principal, and watchlist loans added up to USD 1.1 billion across 11 loans. Sales of two risk-rated 5 loans for USD 310.7 million became binding in October, carrying expected incremental losses of USD 10.4 million. Published market data showed USD 1.87 after a 68.71% one-day rise on 12.921 million shares, all unverified and undated. That level is about 22% of book value, a simple division of USD 1.87 by USD 8.49. No same-day catalyst for the jump has been confirmed, and the earnings release does not declare a common dividend.

SelectQuote (NYSE:SLQT): NYSE Price Notice and a November 10 Reverse Split Vote

SelectQuote (NYSE:SLQT) operates a technology-driven platform that sells Medicare Advantage, life and other insurance policies for carriers. In March 2026 the company disclosed that its average closing price had stayed below USD 1.00 for 30 straight trading days, breaching Section 802.01C of the NYSE Listed Company Manual, which allows a six-month period to fix the problem. The proxy proposes a reverse split between 1-for-10 and 1-for-20, with stockholders voting on November 10, 2026 and a September 18, 2026 record date. A reverse split combines shares so each one carries more value without changing the Business itself. At 1-for-10, a USD 0.52 share would become about USD 5.20 (simple arithmetic that ignores later price changes). The board may decide against proceeding even after approval. Published market data showed a 26.07% jump to USD 0.52 on 2.635 million shares, but no company news accounted for it, and the date is unknown. Current NYSE compliance status and the most recent quarterly results have not been located and are therefore not described.

Where Things Stand

Karyopharm Therapeutics (NASDAQ:KPTI) seeks USD 110 million because its Chapter 11 plan is shaped by lenders and a Merger partner rather than by current shareholders, while the other three stay penny stocks for distinct reasons. Medical Properties Trust (NYSE:MPT) shows a big reported profit alongside weaker normalized FFO and one missed tenant rent payment. Claros Mortgage Trust (NYSE:CMTG) reports a loss, heavy reserves and an unverified price spike. SelectQuote (NYSE:SLQT) faces a split vote that would lift its quoted price without changing the underlying business. In each case the published market data moves are unverified, thinly traded and prone to reversing, so none suggests a trend.